LENZ THERAPEUTICS, INC. Convertible Preferred Stock Converted to Other Securities
LENZ THERAPEUTICS, INC. (LENZ) had Convertible Preferred Stock Converted to Other Securities of $260.50 million as of 2021-06-28, per its 10-K filed 2023-03-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities · last filed 2023-03-20
- 2021-06-28: Convertible Preferred Stock Converted to Other Securities $260.50M.
| Period end | Convertible Preferred Stock Converted to Other Securities |
|---|---|
| 2021-06-28 | $260.50M 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |